Trends and opportunities for pharmaceutical companies: Pharma 2020

From vision to decisionPharma 2020

In this section...

Is pharma's fate sealed?

The outlook has never seemed more promising – or more ominous.

What decisions should you make to successfully launch into 2020?

"It was the best of the times, it was the worst of times..."

Major scientific and technological advances, coupled with socio-demographic changes, increasing demand for medicines and trade liberalisation, will revive pharma's fortunes and deliver dramatic improvements in patient care.

But if the industry is to prosper in the future, it must first make sure it has a future.

Our understanding of breast cancer is being transformed

The market’s getting much tougher, with tighter regulation, harsher price controls and greater government scrutiny.

How will pharma companies overcome these barriers?

Pharma's incurring bigger and more frequent financial penalties in the US

There's arguably a bigger hurdle facing pharma: namely, the rising healthcare bill.

Healthcare expenditure as a percentage of gross domestic product (GDP) is climbing in countries in every income bracket, and it's climbing most steeply in the mature markets where the industry has historically made most of its money.

Healthcare's consuming a larger share of GDP in rich and poor countries alike

Listen to our webcast

Take our poll

Explore the data

Discover the facts and figures from this report

Our interactive graphic allows you to view and compare data for each country mentioned in the report and to compare any six of them.

Download the report

Read the complete analysis

We look at how pharma companies can reach 2020 in a position to benefit from more favourable conditions thereafter - and the most important decisions senior managers will need to make.

Download now